Rapid elicitation of neutralizing Asn332-glycan-independent antibodies to the V3-glycan epitope of HIV-1 Env in nonhuman primates Nature Immunology - WIN332 is an HIV-1 Env protein designed to elicit a new class of Asn332-glycan-independent antibodies (type II) to the V3-glycan site of Env. WIN332 immunization rapidly induces...

Our #WIN332 work is out! 🥳 rdcu.be/e15ti
In this study, led by Ignacio R. Relano, we report WIN332, the first engineered HIV-1 Env immunogen rationally designed to induce a new class of #TypeII #N332-glycan independent #V3-glycan antibodies. #THANKYOU to our collaborators for a great team effort!

Rapid elicitation of a new class of neutralizing N332-glycan independent V3-glycan antibodies against HIV-1 in nonhuman primates. Sequential immunization is a promising approach to elicit broadly neutralizing antibodies (bNAbs) against the HIV-1 Envelope (Env). However, available protocols are inefficient and involve multiple im...

Excited that our preprint is out! 💫 We report #WIN332, the first engineered HIV-1 Env immunogen rationally designed to elicit N332-and N334-glycan independent V3-glycan antibodies.
More ⬇️
www.biorxiv.org/content/10.1...

Philadelphia, PA Location: Philadelphia City Hall City Hall, Philadelphia, PA, United States Time: 11 AM

standupforscience2025.org/philadelphia...

unfortunately not...sorry!

Excited to have presented our work on #WIN332, a new #HIV #vacccine candidate at the annual #CAVD meeting by the Gates Foundation in Tanzania. Even more excited to have spoken for the first time during a session moderated by one of my postdoctoral students, Maria Belen Palacio. Proud of you! 💫 😍

Thank you to the Gates Foundation for featuring 4 of our studies at the annual #CAVD meeting in Tanzania. Congratulations Marta Tarquis Medina, Austin Kriews, Colby Agostino @colby-agostino.bsky.social and Ignacio Rodriguez Relaño, PhD for your Early Career Investigator awards, I am proud of you!